LENZ Therapeutics (LENZ) Stock Forecast, Price Target & Predictions
LENZ Stock Forecast
LENZ Therapeutics stock forecast is as follows: an average price target of $34.00 (represents a -1.88% downside from LENZ’s last price of $34.65) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
LENZ Price Target
The average price target for LENZ Therapeutics (LENZ) is $34.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $36.00 to $32.00. This represents a potential -1.88% downside from LENZ's last price of $34.65.
LENZ Analyst Ratings
According to 4 Wall Street analysts, LENZ Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for LENZ stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
LENZ Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 15, 2024 | Joseph Catanzaro | Piper Sandler | $36.00 | $22.25 | 61.80% | 3.90% |
| Aug 15, 2024 | Yigal Nochomovitz | Citigroup | $32.00 | $23.50 | 36.17% | -7.65% |
The latest LENZ Therapeutics stock forecast, released on Aug 15, 2024 by Joseph Catanzaro from Piper Sandler, set a price target of $36.00, which represents a 61.80% increase from the stock price at the time of the forecast ($22.25), and a 3.90% increase from LENZ last price ($34.65).
LENZ Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $34.00 |
| Last Closing Price | $34.65 | $34.65 | $34.65 |
| Upside/Downside | -100.00% | -100.00% | -1.88% |
In the current month, the average price target of LENZ Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to LENZ Therapeutics's last price of $34.65. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 26, 2024 | Raymond James | - | Outperform | Initialise |
| Aug 15, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 15, 2024 | Citigroup | Buy | Buy | Hold |
| Apr 15, 2024 | William Blair | - | Outperform | Initialise |
| Apr 09, 2024 | Citigroup | - | Buy | Initialise |
LENZ Therapeutics's last stock rating was published by Raymond James on Sep 26, 2024. The company Initialise its LENZ rating from "null" to "Outperform".
LENZ Therapeutics Financial Forecast
LENZ Therapeutics Revenue Forecast
| Revenue |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| # Analysts |
| Surprise % |
LENZ Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. LENZ's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
LENZ Therapeutics EBITDA Forecast
| # Analysts |
| EBITDA |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
undefined analysts predict LENZ's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than LENZ Therapeutics's previous annual EBITDA (undefined) of $NaN.
LENZ Therapeutics Net Income Forecast
| # Analysts |
| Net Income |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
LENZ Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LENZ's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
LENZ Therapeutics SG&A Forecast
| # Analysts |
| SG&A |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
LENZ Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to LENZ last annual SG&A of $NaN (undefined).
LENZ Therapeutics EPS Forecast
| # Analysts |
| EPS |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
According to undefined Wall Street analysts, LENZ Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LENZ previous annual EPS of $NaN (undefined).